Editas Medicine Inc (EDIT)
NASDAQ:EDIT
Want to see EDIT full AI Analyst Report?
Top Page
Editas Medicine
(NASDAQ:EDIT)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.00
▼(-14.04% Downside)
Action:Reiterated
Date:05/14/26
The score is held down primarily by strained fundamentals: very large ongoing losses, significant cash burn, and a materially weakened equity base with higher leverage. Technicals are mixed but not severely bearish, providing some support, while valuation is constrained by negative earnings and no dividend yield data.
Positive Factors
Strong preclinical efficacy for EDIT-401
Robust, durable LDL-C reductions in non-human primates after a single dose indicate EDIT-401 could become a one-time therapy for hyperlipidemia. This materially de-risks the program, strengthens commercial potential in a large cardiometabolic market, and validates the in vivo platform.
Negative Factors
Materially weakened balance sheet
A collapsed equity base and much higher leverage sharply reduce financial flexibility. With a thin equity cushion, adverse trial outcomes or delayed milestones would force dilutive financings or onerous partnership terms, increasing long-term shareholder risk and limiting strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong preclinical efficacy for EDIT-401
Robust, durable LDL-C reductions in non-human primates after a single dose indicate EDIT-401 could become a one-time therapy for hyperlipidemia. This materially de-risks the program, strengthens commercial potential in a large cardiometabolic market, and validates the in vivo platform.
Read all positive factors
Editas Medicine Key Performance Indicators (KPIs)
Any
Operating Expense Breakdown
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment, crucial for understanding Editas Medicine's focus on innovation and operational strategy.
Data provided by:
The Fly
The FlyEditas Medicine (EDIT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$256.51M
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)―
Beta (1Y)2.25
Revenue Growth7.97%
EPS Growth59.82%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding97,906,280
10 Day Avg. Volume1,781,207
30 Day Avg. Volume1,697,905
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)6.67
Price to Sales (P/S)4.49
P/FCF Ratio-1.10
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue5.29
Enterprise Value/Gross Profit5.36
Enterprise Value/Ebitda-2.02
Forecast
1Y Price Target
$6.60Price Target Upside89.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1
Revenue Forecast (FY)$13.98M
Editas Medicine Business Overview & Revenue Model
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company de...
How the Company Makes Money
Editas Medicine’s revenue model has primarily been partnership- and collaboration-driven rather than product-sales-driven, as the company has been clinical-stage and, for much of its history, has not had sustained commercial product revenue. The c...
Editas Medicine Earnings Call Summary
Earnings Call Date:Aug 07, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call highlighted significant progress in both clinical trials and in vivo pipeline development. Financial stability was assured despite a higher burn rate. However, challenges such as increased expenses and regulatory issues around fertility support present hurdles. Overall, the company's advancements in gene editing and robust clinical trial outcomes provide a positive outlook.Positive Updates
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Negative Updates
Increased Burn Rate
Higher burn rate this quarter due to increased external R&D expenses, primarily related to clinical and manufacturing costs.
Read all updates
Q2-2024 Updates
Positive
Negative
Reni-cel Clinical Trials Progress
Completed adolescent cohort enrollment for the RUBY trial, and adult cohort enrollment in the EdiTHAL trial. Clinical data from RUBY and EdiTHAL trials show promising results with all patients free from vaso-occlusive events and a high level of fetal hemoglobin.
Read all positive updates
Company Guidance
During the Editas Medicine Q2 2024 earnings call, CEO Gilmore O'Neill outlined the company's strategic progress, emphasizing three main pillars: advancing reni-cel towards BLA and commercialization, building a differentiated in vivo editing pipeline, and enhancing business development with a focus on intellectual property. The RUBY trial data for sickle cell disease showed promising results, with 18 patients having follow-up periods ranging from 2.4 to 22.8 months and demonstrating robust anemia correction. The EdiTHAL trial for beta-thalassemia included data from 7 patients with 4.1 to 12.8 months follow-up. Financially, Editas reported cash, cash equivalents, and marketable securities totaling $318 million as of June 30, 2024, with a burn rate increase due to R&D expenses. They expect to fund operations into 2026. The company is also on track to establish in vivo preclinical proof of concept by year-end, with a focus on leveraging indel technology for gene upregulation, targeting rare and orphan diseases initially.Editas Medicine Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 38.69M | 40.52M | 32.31M | 78.12M | 19.71M | 25.54M |
| Gross Profit | 38.21M | 40.52M | 32.31M | 72.06M | 13.38M | 20.49M |
| EBITDA | -101.18M | -148.61M | -233.11M | -163.12M | -219.61M | -188.09M |
| Net Income | -108.95M | -160.06M | -237.09M | -153.22M | -220.43M | -192.50M |
Balance Sheet | ||||||
| Total Assets | 149.34M | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M |
| Cash, Cash Equivalents and Short-Term Investments | 123.65M | 146.65M | 269.91M | 323.11M | 344.27M | 499.85M |
| Total Debt | 71.97M | 76.71M | 35.03M | 48.54M | 43.95M | 26.38M |
| Total Liabilities | 144.93M | 159.25M | 207.31M | 150.06M | 153.64M | 123.84M |
| Stockholders Equity | 4.41M | 27.29M | 134.27M | 349.10M | 360.68M | 553.64M |
Cash Flow | ||||||
| Free Cash Flow | -141.09M | -165.85M | -219.11M | -136.90M | -181.47M | -171.78M |
| Operating Cash Flow | -140.50M | -165.24M | -210.28M | -132.18M | -177.35M | -163.80M |
| Investing Cash Flow | 82.34M | 138.67M | 162.15M | -3.73M | 114.07M | -54.47M |
| Financing Cash Flow | 41.91M | 40.47M | 56.03M | 118.04M | 1.28M | 282.11M |
Editas Medicine Technical Analysis
Positive
3.49
Price Trends
2.34
Positive
2.28
Positive
2.63
Positive
Market Momentum
0.30
Negative
80.03
Negative
83.28
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EDIT, the sentiment is Positive. The current price of 3.49 is above the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.34, and above the 200-day MA of 2.63, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 80.03 is Negative, neither overbought nor oversold. The STOCH value of 83.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EDIT.
Editas Medicine Risk Analysis
Editas Medicine disclosed 72 risk factors in its most recent earnings report. Editas Medicine reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Editas Medicine Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $792.74M | -0.87 | 72.70% | ― | ― | -1004.74% | |
46 Neutral | $256.51M | -2.42 | -677.38% | ― | 7.97% | 59.82% | |
46 Neutral | $301.27M | -4.47 | -69.63% | ― | 43.21% | -15.55% | |
46 Neutral | $222.53M | -4.18 | 85.78% | ― | 20.08% | 14.06% | |
46 Neutral | $202.89M | -4.12 | -977.67% | ― | ― | 43.68% | |
45 Neutral | $212.25M | -1.82 | -100.13% | ― | 12.96% | 12.51% |
* Healthcare Sector Average
EDIT
Editas Medicine
2.62
1.11
73.51%
CLLS
Cellectis SA
3.92
2.34
148.10%
FHTX
Foghorn Therapeutics
3.79
-0.64
-14.45%
ELTX
Elicio Therapeutics
10.63
5.30
99.44%
VOR
Vor Biopharma
14.63
11.09
313.28%
CRBU
Caribou Biosciences
2.14
1.20
127.66%
Editas Medicine Corporate Events
Business Operations and StrategyProduct-Related Announcements
Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data
Positive
May 14, 2026
On May 14, 2026, at the American Society of Gene and Cell Therapy Annual Meeting, Editas Medicine reported new preclinical data for its lead in vivo candidate EDIT-401 as a potential one-time treatment for hyperlipidemia, showing 90% or greater me...
Business Operations and StrategyLegal Proceedings
USPTO Ruling Impacts Editas Medicine CRISPR IP Position
Negative
Mar 27, 2026
Editas Medicine, Inc. is a biotechnology company focused on developing gene-editing therapies based on CRISPR/Cas9 technology. It operates in the genomic medicine industry, aiming to translate gene-editing innovations into treatments for human dis...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.